Opinion Article: Opening Up to Open Source

IMS MAXIMSBy Shane Tickell, CEO of IMS MAXIMS.
A year ago I declared that IMS MAXIMS was considering making its MAXIMS PAS and EPR available as an open source solution to the NHS. At that point, we were "far from committed to the model" but were engaging with our customers, sounding out the market and getting to grips with the benefits for both IMS MAXIMS and the wider health economy.

Our open source strategy has been developed with the vision of encouraging more innovation in the health service and facilitating the transition to a safer, patient focused, paperless NHS. And this flexible approach has already taken us on an incredible journey. We have received significant interest from NHS trusts, are working closely with NHS England, have made our open source solution set, openMAXIMS, available on GitHub, signed a contract with Taunton and Somerset NHS Foundation Trust and are now working with numerous others. To date, we are effectively the only British open source PAS and EPR supplier on the market.

What we have realised over the last twelve months is that open source is simply another vehicle to achieving a paperless NHS that delivers better, safer, patient care. This has been demonstrated by feedback at a number of events we have hosted, where guests had not attended just because they were specifically interested in open source. Instead they said it was because they wanted an EPR that they could tailor to their own needs and that could deliver benefits to patients and staff alike.

The recent announcement by electronic car company, Tesla Motors, has really resonated with IMS MAXIMS. Last month, the car manufacturer announced that it would open source the company's entire patent portfolio as part of its wider aim to accelerate the advent of sustainable transport.

Tesla do not see other electronic car providers as a threat but rather sees petrol and diesel car manufacturers as a danger to sustainable transport models. In the same way, IMS MAXIMS does not necessarily see other PAS and EPRs companies as competitors but sees paper and inefficiency in the NHS as an increasing threat to providing better, safe care.

In his blog, Tesla's CEO Elon Musk, wrote: "Putting in long hours for a corporation is hard but putting in long hours for a cause is easy" and that has certainly been true of so many of the people we work with, both internally and within the NHS, with regards to open source.

But despite our commitment there is, of course, still some resistance from the NHS and suppliers alike in the adoption of open source. And as the adoption of new technologies can take decades in the NHS, this resistance should be expected. It is now a matter of continuing to demystify the concerns about potential risk and being as transparent as possible.

The current perception amongst many is that taking an open source approach will mean that organisations will have to take the code and create developers and support teams in-house. With our model, this is simply not the case. Not only do we exist to assist on information governance, security issues and connectivity but also to provide implementation and support services.

Some of the most commonly asked questions that come up time and time again by those considering open source are about the future of the openMAXIMS - do the IMS MAXIMS development team stop there? Is there a roadmap? If ePrescribing isn't included in it now, do we have to build it?

From our point of view, becoming open source is not about saying, "here you go - do what you want with it?" It is about opening the solution up to scrutiny, creating a community and in turn mainstreaming improvement through development.

We have every ambition to take the product to a point that enables trusts that use it to travel higher up the Clinical Digital Maturity Index and beyond. Ultimately, the roadmap is ours to deliver but by enabling the NHS to have greater input and influence on that roadmap, we can apply the transfer of good practice.

Musk provided a valuable lesson from Tesla's strategy: "Technology leadership is not defined by patents, which history has repeatedly shown to be small protection against a determined competitor, but rather the ability to attract and motivate the world’s most talented engineers."

And the more users we have of our solutions, the more expertise, input and enhancements we will have.

One year on from our initial considerations, our open source journey is still in its infancy. But with significant interest from trusts looking to use Tech Fund 2 funding for such a solution and an NHS organisation looking to utilise our open source solution, the misconceptions are slowly being addressed and a better understanding of how it can meet the aim of improving patient outcomes is slowly being realised. If interest continues at this rate, we have no doubt that open source in the NHS is here to stay.

IMS MAXIMS is open to answering any further questions the NHS has, please tweet them to @openmaxims

About IMS MAXIMS
IMS MAXIMS is an electronic patient record provider working towards better, safer patient care. Specialists in developing clinical and administrative software solutions for healthcare providers, IMS MAXIMS, currently supports more than 150 organisations, 11 million patient records in the UK, and 1.9 million patient records in Ireland, approx. 50% of the population, as well as 20,000 users of IMS MAXIMS products.

MAXIMS is at the heart of the clinical and administrative life of everything from large UK and Irish hospitals, to small specialist independent clinics. It gives patient data to clinicians in the exact format they need and allows it to be shared with colleagues and updated in real-time. MAXIMS suits any clinical specialist and is excellent for order communications and reporting. Medical and administrative records can be kept fully up to date with minimum effort, providing the clearest picture of patient’s care. MAXIMS is web-based so there is no need to install software on computers or invest in expensive extra hardware.

IMS MAXIMS also offers the full MAXIMS suite as free-of-charge open source software product openMAXIMS. The open source solution is identical to the exclusive range of products in all aspects but allows the organisations economical relief as it has the full functionality without the licence fee.

Most Popular Now

Open Call HORIZON-MISS-2022-CANCER-01-04…

The overall goal of the Mission on Cancer[1] and the Europe's Beating Cancer Plan[2] includes a better quality of life for patients and their families living with, and after, cancer. Project...

Researchers Use AI to Predict Cancer Ris…

An artificial intelligence (AI) tool helps doctors predict the cancer risk in lung nodules seen on CT, according to a new study published in the journal Radiology. Pulmonary nodules appear as...

Insilico Medicine Raises $60 Million in …

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with...

Speech Analysis App Predicts Worsening H…

A voice analysis app used by heart failure patients at home recognises fluid in the lungs three weeks before an unplanned hospitalisation or escalation in outpatient drug treatment. The late...

Siemens Healthineers and Penta Hospitals…

Penta Hospitals International, the largest multi-national hospital chain in Central and Eastern Europe, agreed a strategic partnership with Siemens Healthineers valued at over 30 million euros. Penta Hospitals International operates...

Screening for Diabetic Retinopathy Prove…

Both telemedicine and community screening for diabetic retinopathy (DR) in rural and urban settings are cost-effective in China, and telemedicine screening programs are more cost-effective, according to a study led...

KTU Researchers Investigate the Links Be…

In recent years Alzheimer's disease has been on the rise throughout the world and is rarely diagnosed at an early stage when it can still be effectively controlled. Using artificial...

Researchers Develop Smartphone-Powered M…

A University of Minnesota Twin Cities research team has developed a new microfluidic chip for diagnosing diseases that uses a minimal number of components and can be powered wirelessly by...

Philips' Future Health Index 2022 Report…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the publication of its Future Health Index (FHI) 2022 report: 'Healthcare hits reset: Priorities shift as...

App Detecting Jaundice in Babies a Succe…

A smartphone app that identifies severe jaundice in newborn babies by scanning their eyes could be a life-saver in areas that lack access to expensive screening devices, suggests a study...

InterSystems Wins Data Driven Product of…

InterSystems, a provider of next-generation solutions for enterprise digital transformation to help customers solve the most critical data challenges, has announced it received the prestigious Data Driven Product of the...